Skip to main content
Premium Trial:

Request an Annual Quote

Fresh from Spin-off, Pharmacopeia and PDD Post Decline in Revenues

NEW YORK, May 4 (GenomeWeb News) - Following on yesterday's spin-off of Pharmacopeia Drug Discovery from parent company Pharmacopeia, the newly separate companies today reported lower revenues in the quarter ended March 31, 2004, when compared to the same period of 2003.

Pharmacopeia - now trading under the ticker symbol ACCL, and soon to be renamed Accelrys - posted software sales of $11.1 million for the three months ended March 31, 2004, down from $17.2 million in the year-ago quarter.

Revenues at PDD were also down year-over-year, to $5.4 million for the quarter, compared to $7.5 million for the quarter ended March 31, 2003.

Pharmacopeia's losses widened dramatically to $26.8 million for the quarter ended March 31, 2004, compared to $5.5 million in the prior-year period. The current-year loss included $900,000 in relocation costs, $11.1 million of restructuring and other charges, and $2.3 million in spin-off transaction costs. The company did not provide net losses for PDD.

Pharmacopeia's research and development expenses were flat year-over-year, at $5.7 million.

The company had $141.6 million in cash, cash equivalents, and marketable securities as of March 31, 2004, compared to $134.1 million as of Dec. 31. 2003.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.